Rounds of trial-and-error exploring the layer of cells covering the ovary leave open questions about stem cells that are associated with ovarian cancer.
Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial.
Clinical trials were halted after the treatment’s vector that ferries in the healthy genetic sequence was identified in the genome of a patient’s cancer cells.